Thyroid Eye Disease

Phase 3 Clinical Study: Horizon-TEP-301

NOW RECRUITING

- Do you have a patient with proptosis due to Thyroid Eye Disease within 9 months onset of the proptosis?
- We are using a human monoclonal AB, Teprotumumab, given by IV infusion.



To qualify, the patient must:

- □ **be 18 to 75 years old**
- □ **have proptosis in one or both eyes due to Thyroid Eye Disease**

. Study info:

- □ **All study participants will be assigned to receive infusions (sham included) for a period of 24 weeks with 8 infusions, then they will be monitored for an additional 5 visits over the following year (Total study duration = 72 weeks)**
- □ **Non-Responders and/or Sham-controlled participants will be offered the opportunity to be given the drug in an open label study for a subsequent 24 week infusion period, post-initial infusion period, then they will be monitored for an additional 5 visits over the following year (Total study duration = 96 weeks)**
- □ **All study related costs are covered; Reasonable patient travel costs may be reimbursed.**
- □ **For additional information, refer to Smith TJ, Tang RA, et al. "Teprotumumab for Thyroid-Associated Ophthalmopathy." New England Journal of Medicine 376.18 (2017): 1748-1761.**

To refer patients to this study, please contact:

PI: Rosa Tang, MD MPH MBA
Direct: (281) 650-4529
rtang@neuroeye.com

SC: Alonso Prusmack, BS COA OSC
Direct: (713) 480-0218
aprusmack@neuroeye.com